文献速递角膜与眼表疾病青光眼

既往青光眼手术后内皮角膜移植术的系统评价与荟萃分析:按移植技术分层

Endothelial Keratoplasty in Eyes With Previous Glaucoma Surgery: A Systematic Review and Meta-Analysis Stratified by Graft Technique.
PubMed 文献 · Am J Ophthalmol · 2026-09-12

总体36个月移植物存活率为57%,青光眼引流装置植入眼为50%。GDD眼6个月和12个月内皮细胞丢失分别达53%和63%,移植物脱位率19%。

要点

  • 既往青光眼手术眼行EK后36个月总体移植物存活率为57%,GDD眼仅50%。
  • GDD眼6个月和12个月内皮细胞丢失分别达53%和63%。
  • GDD眼移植物脱位率19%高于总体队列的15%。

核心结论

  • 仅半数GDD眼在36个月时移植物仍存活。
  • 需要采用标准化终点的前瞻性注册研究。

研究设计与样本

  • 系统评价与荟萃分析(PROSPERO CRD420251118709),检索PubMed/MEDLINE、Scopus、Cochrane和Web of Science至2026年4月。
  • 采用随机效应模型,比例使用Freeman-Tukey转换,必要时从Kaplan-Meier曲线提取移植物存活数据。

主要发现

  • 总体队列36个月移植物存活率为57%(95% CI,48%-66%),既往GDD植入眼为50%(95% CI,42%-57%)。
  • 间接技术分层估计从24个月起数值上偏向DSAEK,尤其在GDD眼。
  • 头对头分析显示总体队列至24个月两种技术间无显著差异。
  • GDD眼6个月和12个月内皮细胞丢失分别达53%和63%。
  • GDD眼移植物脱位率为19%,总体队列为15%;排斥率为8%-9%,原发性移植物失败率为4%-5%。

关键数值与推荐

  • 纳入标准:报告DSAEK或DMEK在既往青光眼手术眼中结局且随访至少6个月的研究。
  • 主要结局为移植物存活,次要结局包括内皮细胞密度、内皮细胞丢失、移植物脱位、排斥和原发性移植物失败。

临床怎么用

  • 应为既往青光眼手术(尤其GDD)眼行EK的患者提供关于移植物存活率较低和内皮细胞丢失较快的风险咨询。
  • 技术选择可参考间接比较中DSAEK在24个月后数值上略优的趋势,但头对头分析至24个月未见显著差异。

局限性

  • 纳入研究均为回顾性研究。
  • 现有系列样本量小、异质性高,单个研究不足以指导风险咨询或技术选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: To pool estimates of graft survival, endothelial cell loss, and complication rates following endothelial keratoplasty (EK) in eyes with prior glaucoma surgery, and to compare outcomes between Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK). CLINICAL RELEVANCE: EK after glaucoma surgery carries elevated graft failure risk, yet existing series are small, heterogeneous, and individually insufficient to guide risk counseling or technique selection. No pooled synthesis exists to date. METHODS: Systematic review and meta-analysis (PROSPERO CRD420251118709) searching PubMed/MEDLINE, Scopus, Cochrane, and Web of Science to April 2026. Eligible studies reported DSAEK or DMEK outcomes in eyes with prior glaucoma surgery with minimum 6-month follow-up. Primary outcome was graft survival, extracted from Kaplan-Meier curves where necessary. Secondary outcomes included endothelial cell density, endothelial cell loss, graft dislocation, rejection, and primary graft failure, analyzed using a random-effects model with Freeman-Tukey transformation for proportions. Head-to-head risk ratios were pooled from studies reporting both techniques. RESULTS: Twenty-two retrospective studies (943 grafts; 656 DSAEK, 287 DMEK) were included. Pooled 36-month graft survival was 57% (95% CI, 48%-66%) in the overall cohort and 50% (95% CI, 42%-57%) in eyes with prior glaucoma drainage device (GDD) implantation. Indirect technique-stratified estimates numerically favored DSAEK from 24 months, particularly in GDD eyes. Head-to-head analysis found no significant difference through 24 months in the overall cohort. Pooled endothelial cell loss reached 53% at 6 months and 63% at 12 months in GDD eyes. Graft dislocation was higher in GDD eyes (19%) than in the overall cohort (15%). Rejection rates were 8%-9%, and primary graft failure remained low (4%-5%). CONCLUSION: Only half of GDD eyes retain a functioning graft at 36 months. Prospective registries with standardized endpoints are needed.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Irigoyen-Bañegil C, Jiménez-Alfaro M, Naveiras M, et al. Endothelial Keratoplasty in Eyes With Previous Glaucoma Surgery: A Systematic Review and Meta-Analysis Stratified by Graft Technique. Am J Ophthalmol. 2026. PMID: 42731771. doi:10.1016/j.ajo.2026.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。